Found: 37
Select item for more details and to access through your institution.
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 9, p. 1746, doi. 10.1002/ajh.27382
- By:
- Publication type:
- Article
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 1, p. 73, doi. 10.1111/ejh.13706
- By:
- Publication type:
- Article
Bone lesions in hairy cell leukemia: Diagnosis and treatment.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 6, p. 682, doi. 10.1111/ejh.13505
- By:
- Publication type:
- Article
An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma.
- Published in:
- Contemporary Oncology / Współczesna Onkologia, 2023, v. 27, n. 3, p. 139, doi. 10.5114/wo.2023.133506
- By:
- Publication type:
- Article
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases.
- Published in:
- Molecules, 2009, v. 14, n. 3, p. 1183, doi. 10.3390/molecules14031183
- By:
- Publication type:
- Article
TROSKA KOŚCIOŁA KATOLICKIEGO O OSOBY Z NIEPEŁNOSPRAWNOŚCIĄ.
- Published in:
- Church & Law / Kościół i Prawo, 2022, v. 11, n. 2, p. 253, doi. 10.18290/kip22112.15
- By:
- Publication type:
- Article
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.
- Published in:
- Mediators of Inflammation, 2020, p. 1, doi. 10.1155/2020/1835836
- By:
- Publication type:
- Article
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 2938, doi. 10.3390/ijms24032938
- By:
- Publication type:
- Article
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 21, p. 12070, doi. 10.3390/ijms222112070
- By:
- Publication type:
- Article
Current and Emerging Treatments for Chronic Lymphocytic Leukaemia.
- Published in:
- Drugs, 2009, v. 69, n. 17, p. 2415, doi. 10.2165/11319270-000000000-00000
- By:
- Publication type:
- Article
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2023
- By:
- Publication type:
- journal article
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02337-5
- By:
- Publication type:
- Article
Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.
- Published in:
- Oncology Letters, 2017, v. 13, n. 4, p. 2079, doi. 10.3892/ol.2017.5725
- By:
- Publication type:
- Article
Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro.
- Published in:
- Journal of Chemistry, 2015, v. 2015, p. 1, doi. 10.1155/2015/162956
- By:
- Publication type:
- Article
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
- Published in:
- BioDrugs, 2016, v. 30, n. 2, p. 87, doi. 10.1007/s40259-016-0165-6
- By:
- Publication type:
- Article
Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.976374
- By:
- Publication type:
- Article
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
- Published in:
- Polish Archives of Internal Medicine, 2024, v. 134, n. 5, p. 1, doi. 10.20452/pamw.16749
- By:
- Publication type:
- Article
Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a "real-world" study: experiences of the Polish Myeloma Group.
- Published in:
- Polish Archives of Internal Medicine, 2021, v. 131, n. 6, p. 527, doi. 10.20452/pamw.15980
- By:
- Publication type:
- Article
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 5, p. 792, doi. 10.1111/bjh.19097
- By:
- Publication type:
- Article
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 6, p. 831, doi. 10.1111/bjh.15092
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 884, doi. 10.1111/bjh.14328
- By:
- Publication type:
- Article
Blokady centralne u dorosłych Odcinek szyjny.
- Published in:
- Anaesthesiology & Rescue Medicine / Anestezjologia i Ratownictwo, 2020, v. 14, n. 1, p. 46
- By:
- Publication type:
- Article
Blokady centralne u dorosłych. Odcinek piersiowy.
- Published in:
- Anaesthesiology & Rescue Medicine / Anestezjologia i Ratownictwo, 2019, v. 13, n. 3, p. 254
- By:
- Publication type:
- Article
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
- Published in:
- Medical Oncology, 2012, v. 29, n. 3, p. 2111, doi. 10.1007/s12032-011-0105-8
- By:
- Publication type:
- Article
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
- Published in:
- Drugs in R&D, 2019, v. 19, n. 2, p. 73, doi. 10.1007/s40268-019-0269-9
- By:
- Publication type:
- Article
Incidence and predictors of severe infectious complications in relapsed//refractory multiple myeloma treated with lenalidomide and dexamethasone (Rd) regimen ― a single-center, retrospective, real-life study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 89
- By:
- Publication type:
- Article
Atypical Chronic Lymphocytic Leukemia—The Current Status.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4427, doi. 10.3390/cancers15184427
- By:
- Publication type:
- Article
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4359, doi. 10.3390/cancers15174359
- By:
- Publication type:
- Article
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 951, doi. 10.3390/cancers13050951
- By:
- Publication type:
- Article
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2569, doi. 10.3390/cancers12092569
- By:
- Publication type:
- Article
Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 23, p. 6983, doi. 10.3390/jcm11236983
- By:
- Publication type:
- Article
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 19, p. 5908, doi. 10.3390/jcm11195908
- By:
- Publication type:
- Article
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 112, doi. 10.3390/jcm11010112
- By:
- Publication type:
- Article
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 21, p. 5028, doi. 10.3390/jcm10215028
- By:
- Publication type:
- Article
Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
- Published in:
- 2021
- By:
- Publication type:
- case study
The evaluation and optimal use of rituximab in lymphoid malignancies.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2012, v. 2, p. 1, doi. 10.2147/BLCTT.S15561
- By:
- Publication type:
- Article
Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors.
- Published in:
- Molecular Medicine Reports, 2019, v. 19, n. 5, p. 3593
- By:
- Publication type:
- Article